株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

米国の麻酔薬市場・予測

United States Anesthesia Drugs Market & Forecast

発行 Renub Research 商品コード 320845
出版日 ページ情報 英文 127 Pages; 55 Figures; 16 Tables
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.38円で換算しております。
Back to Top
米国の麻酔薬市場・予測 United States Anesthesia Drugs Market & Forecast
出版日: 2017年06月12日 ページ情報: 英文 127 Pages; 55 Figures; 16 Tables
概要

当レポートでは、米国の麻酔薬市場について調査し、市場シェア・予測、種類・薬剤別の市場分析、市場成長促進因子と課題、および主要企業のプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 米国の麻酔薬市場

第3章 米国の麻酔薬市場シェア・予測

  • 麻酔薬市場シェア・予測:種類別
  • 全身静脈麻酔薬市場シェア・予測
  • 局所麻酔薬市場シェア・予測
  • 麻酔薬市場シェア・予測:企業別

第4章 種類別:米国の麻酔薬市場

  • 全身吸入麻酔薬市場
  • 全身静脈麻酔薬市場
  • 局所麻酔薬市場

第5章 薬剤別:米国の全身静脈麻酔薬市場

  • プロポフォール市場
  • ベンゾジアゼピンクラス(ジアゼパム・ミダゾラム)市場
  • フォスプロポフォール2ナトリウム市場
  • ケタミン市場
  • メトヘキシタールナトリウム市場
  • ペントバルビタール市場
  • エトミデート市場
  • フェンタニル市場

第6章 薬剤別:米国の局所麻酔薬市場

  • アルチカイン市場
  • ブピバカイン市場
  • リドカイン市場
  • メピバカイン市場
  • プリロカイン市場

第7章 米国の麻酔薬市場における主要企業のプロファイル

  • Baxter International Inc.
  • Endo Health Solutions Inc.
  • Abbott Laboratories
  • AstraZeneca

第8章 米国の麻酔薬市場におけるM&A

第9章 米国における麻酔薬の償還政策:民間医療保険プロバイダー

  • Aetna International
  • Coventry Health Care
  • Anthem Blue Cross and Blue Shield
  • Blue Cross and Blue Shield of Texas
  • UnitedHealthcare

第10章 米国における麻酔薬の償還政策:公的医療保険プロバイダー

  • Medicare
  • MDWise

第11章 米国の麻酔薬市場:成長促進因子

第12章 米国の麻酔薬市場:課題

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

United States Anesthesia Market is expected to be more than US$ 4 Billion by 2022. This growth is driven by increasing incidence of cardiovascular cases, growing old age population and rising number of urgent surgeries in United States. Private as well as public health insurers also help to boost this market as they consider anesthetic products in their reimbursement policy.

General Intravenous Anesthesia is the Leading Segments in the United States Anesthesia Market

General intravenous anesthesia is the leading segments in the United States Anesthesia Market. Propofol, Benzodiazepines Class, Fospropofol Disodium, Ketamine, Methohexital Sodium, Pentobarbital, Etomidate and Fentanyl are commonly used general intravenous anesthesia in the United States. Among these anesthesia, Propofol and Benzodiazepines Class are the leading anesthesia drugs which hold more than 75 percent combined market share in 2016.

Major Anesthesia Drug's Manufacturers are continuously losing their Sales in United Sates

In the United States anesthesia drugs market several players are selling their products. Most of the anesthesia drugs sale are in generic form as it is available in the low cost. However all major drugs manufactures such as AstraZeneca, AbbVie , Endo Healthcare etc. anesthesia products sales are turning down continuously. Only Baxter International anesthesia drugs sales are growing in the United States market.

United States Anesthesia Drugs Market & Forecast is the 22nd edition report on United States Anesthesia Market published by Renub Research. This 127 page report with 55 Figures and 16 Tables provides a detailed analysis of local and general anesthesia drugs market, health insurers' anesthesia reimbursement policies, eligibility criteria and reimbursement methods in United States. This report has been studied from 8 viewpoints.

  • 1. United Sates Anesthesia Market
  • 2. United Sates Anesthesia Drugs Share Analysis
  • 3. General Anesthesia Market
  • 4. Local Anesthesia Market
  • 5. Anesthesia Reimbursement Policy by Health Insurance Companies (Private & Public)
  • 6. Major Companies Anesthesia Sales
  • 7. United States Anesthesia Market Drivers
  • 8. United States Anesthesia Market Challenges

General Intravenous Anesthetic Drugs Market has been further divided into

  • 1. Propofol Market (2011 - 2022)
  • 2. Benzodiazepines Class (Diazepam and Midazolam) (2011 - 2022)
  • 3. Fospropofol Disodium (2011 - 2022)
  • 4. Ketamine (2011 - 2022)
  • 5. Methohexital Sodium (2011 - 2022)
  • 6. Pentobarbital (2011 - 2022)
  • 7. Etomidate (2011 - 2022)
  • 8. Fentanyl (2011 - 2022)

United States Local Anesthetic Market has been further divided into

  • 1. Articane (2011 - 2022)
  • 2. Bupivacaine (2011 - 2022)
  • 3. Lidocaine (2011 - 2022)
  • 4. Mepivacaine (2011 - 2022)
  • 5. Prilocaine (2011 - 2022)

Key Players Sales in United States Anesthetic Drugs Market

  • 1. Baxter International Inc (2011 - 2022)
  • 2. Endo Health Solutions Inc (2011 - 2022)
  • 3. AbbVie (2011 - 2022)
  • 4. AstraZeneca (2011 - 2022)

This report provides the answer of following questions:

  • Which one is the leading market (Local anesthesia or general Anesthesia) in the United States Anesthesia market?
  • Which is the leading local anesthesia drug in United States Local Anesthesia Market?
  • Which is the leading General anesthesia drug in United States General Anesthesia Market?
  • What is the market size of each anesthesia drugs during 2011 - 2022?
  • What is the reimbursement policy on anesthetic services in the United States?
  • What are the anesthesia drugs sales situations in United States for key anesthesia players?
  • What is the reimbursements policy in United States for Anesthesia by Private and Public Insurers

Table of Contents

1. Executive Summary

2. United States Anesthesia Drugs Market (2011 - 2022)

3. United States Anesthesia Drugs Market Share & Forecast (2011 - 2022)

  • 3.1. United States Anesthesia Drugs Market Share & Forecast by Type (2011 - 2022)
  • 3.2. United States General Intravenous Anesthesia Drugs Market Share & Forecast (2011 - 2022)
  • 3.3. United States Local Anesthesia Drugs Market Share & Forecast (2011 - 2022)
  • 3.4. United States Anesthesia Drugs Market Share & Forecast by Company (2011 - 2022)

4. By Type - United States Anesthesia Drugs Market (2011 - 2022)

  • 4.1. United States General Inhalation Anesthesia Drugs Market (2011 - 2022)
  • 4.2. United States General Intravenous Anesthesia Drugs Market (2011 - 2022)
  • 4.3. United States Local Anesthesia Drugs Market (2011 - 2022)

5. By Drugs - United States General Intravenous Anesthesia Drugs Market (2011 - 2022)

  • 5.1. United States Propofol Market (2011 - 2022)
  • 5.2. United States Benzodiazepines Class (Diazepam and Midazolam) Market (2011 - 2022)
  • 5.3. United States Fospropofol Disodium Market (2011 - 2022)
  • 5.4. United States Ketamine Market (2011 - 2022)
  • 5.5. United States Methohexital Sodium Market (2011 - 2022)
  • 5.6. United States Pentobarbital Market (2011 - 2022)
  • 5.7. United States Etomidate Market (2011 - 2022)
  • 5.8. United States Fentanyl Market (2011 - 2022)

6. By Drugs - United States Local Anesthesia Drugs Market (2011 - 2022)

  • 6.1. United States Articaine Market (2011 - 2022)
  • 6.2. United States Bupivacaine Market (2011 - 2022)
  • 6.3. United States Lidocaine Market (2011 - 2022)
  • 6.4. United States Mepivacaine Market (2011 - 2022)
  • 6.5. United States Prilocaine Market (2011 - 2022)

7. Key Players Profile in United States Anesthesia Drugs Market

  • 7.1. Baxter International Inc. Anesthesia Drugs Sales & Forecast (2011 - 2022)
  • 7.2. Endo Health Solutions Inc. Anesthesia Drugs Sales & Forecast (2011 - 2022)
  • 7.3. AbbVie Anesthesia Drugs Sales & Forecast (2011 - 2022)
  • 7.4. AstraZeneca Anesthetic Drugs Sales (2009 - 2011)

8. United States Anesthesia market Merger & Acquisition (M&A)

9. United States Anesthesia Reimbursement Policy - Private Health Insurance Providers

  • 9.1. Aetna International
  • 9.2. Coventry Health Care
  • 9.3. Anthem Blue Cross and Blue Shield
  • 9.4. Blue Cross and Blue Shield of Texas
  • 9.5. UnitedHealthcare
    • 9.5.1. State Exceptions

10. United States Anesthesia Reimbursement Policy - Public Health Insurance Providers

  • 10.1. Medicare
  • 10.2. MDWise

11. United States Anesthesia Drugs Market - Growth Drivers

  • 11.1. Growing Demand for Anesthesia Service
  • 11.2. Rise in Ageing Population & Prevalence of Cardiovascular Disease in United States
    • 11.2.1. Rise in Ageing Population

12. United States Anesthesia Drugs Market - Challenges

  • 12.1. Un-match Anesthesia Providers in United States
  • 12.2. Shortage of Anesthesia Drugs in United States

List of Figures:

  • Figure 2-1: United States-Anesthesia Drugs Market (Million US$), 2011-2016
  • Figure 2-2: United States-Forecast for Anesthesia Drugs Market (Million US$), 2017-2022
  • Figure 3-1: United States-Anesthesia Drugs Market Share by Type (Percent), 2011-2016
  • Figure 3-2: United States-Forecast for Anesthesia Drugs Market Share by Type (Percent), 2017-2022
  • Figure 3-3: United States-General Intravenous Anesthesia Drugs Market Share (Percent), 2011-2016
  • Figure 3-4: United States-Forecast for General Intravenous Anesthesia Drugs Market Share (Percent), 2017-2022
  • Figure 3-5: United States-Local Anesthesia Drugs Market Share (Percent), 2011-2016
  • Figure 3-6: United States-Forecast for Local Anesthesia Drugs Market Share (Percent), 2017-2022
  • Figure 3-7: United States-Anesthesia Drugs Market Share by Company (Percent), 2011-2016
  • Figure 3-8: United States-Forecast for Anesthesia Drugs Market Share by Company (Percent), 2017-2022
  • Figure 4-1: United States-General Inhalation Anesthesia Drugs Market (Million US$), 2011-2016
  • Figure 4-2: United States-Forecast for General Inhalation Anesthesia Drugs Market (Million US$), 2017-2022
  • Figure 4-3: United States-General Intravenous Anesthesia Drugs Market (Million US$), 2011-2016
  • Figure 4-4: United States-Forecast for General Intravenous Anesthesia Drugs Market (Million US$), 2017-2022
  • Figure 4-5: United States-Local Anesthesia Drugs Market (Million US$), 2011-2016
  • Figure 4-6: United States-Forecast for Local Anesthesia Drugs Market (Million US$), 2017-2022
  • Figure 5-1: United States-Propofol Market (Million US$), 2011-2016
  • Figure 5-2: United States-Forecast for Propofol Market (Million US$), 2017-2022
  • Figure 5-3: United States-Benzodiazepines Class Market (Million US$), 2011-2016
  • Figure 5-4: United States-Forecast for Benzodiazepines Class Market (Million US$), 2017-2022
  • Figure 5-5: United States-Fospropofol Disodium Market (Million US$), 2011-2016
  • Figure 5-6: United States-Forecast for Fospropofol Disodium Market (Million US$), 2017-2022
  • Figure 5-7: United States-Ketamine Market (Million US$), 2011-2016
  • Figure 5-8: United States-Forecast for Ketamine Market (Million US$), 2017-2022
  • Figure 5-9: United States-Methohexital Sodium Market (Million US$), 2011-2016
  • Figure 5-10: United States-Forecast for Methohexital Sodium Market (Million US$), 2017-2022
  • Figure 5-11: United States-Pentobarbital Market (Million US$), 2011-2016
  • Figure 5-12: United States-Forecast for Pentobarbital Market (Million US$), 2017-2022
  • Figure 5-13: United States-Etomidate Market (Million US$), 2011-2016
  • Figure 5-14: United States-Forecast for Etomidate Market (Million US$), 2017-2022
  • Figure 5-15: United States-Fentanyl Market (Million US$), 2011-2016
  • Figure 5-16: United States-Forecast for Fentanyl Market (Million US$), 2017-2022
  • Figure 6-1: United States-Articaine Market (Million US$), 2011-2016
  • Figure 6-2: United States-Forecast for Articane Market (Million US$), 2017-2022
  • Figure 6-3: United States-Bupivacaine Market (Million US$), 2011-2016
  • Figure 6-4: United States-Forecast for Bupivacaine Market (Million US$), 2017-2022
  • Figure 6-5: United States-Lidocaine Market (Million US$), 2011-2016
  • Figure 6-6: United States-Forecast for Lidocaine Market (Million US$), 2017-2022
  • Figure 6-7: United States-Mepivacaine Market (Million US$), 2011-2016
  • Figure 6-8: United States-Forecast for Mepivacaine Market (Million US$), 2017-2022
  • Figure 6-9: United States-Prilocaine Market (Million US$), 2011-2016
  • Figure 6-10: United States-Forecast for Prilocaine Market (Million US$), 2017-2022
  • Figure 7-1: United States-Baxter International Anesthesia Drugs Sales (Million US$), 2011-2016
  • Figure 7-2: United States-Forecast for Baxter International Anesthesia Drugs Sales (Million US$), 2017-2022
  • Figure 7-3: United States-Endo Health Solutions Anesthesia Drugs Sales (Million US$), 2011-2016
  • Figure 7-4: United States-Forecast for Endo Health Solutions Anesthesia Drugs Sales (Million US$), 2017-2022
  • Figure 7-5: United States-AbbVie Anesthesia Drugs Sales (Million US$), 2011-2016
  • Figure 7-6: United States-Forecast for AbbVie Anesthesia Drugs Sales (Million US$), 2017-2022
  • Figure 7-7: United States-AstraZeneca Anesthesia Drugs Sales (Million US$), 2009-2011
  • Figure 11-1: United States-Cosmetic Procedures (Number), 1997, 2012-2013, 2015-2016
  • Figure 11-3: United States-Ageing Population by Age Group (Thousand), 2012-2016
  • Figure 12-1: United States-By Region Availability of Anesthesia Specialists (Percent), 2010
  • Figure 12-2: United States-By States Availability of Anesthesia Specialists (Percent), 2010
  • Figure 12-3: United States-Drugs Shortage (Number), 2001-2015
  • Figure 12-4: United States-Anesthesia Drugs Shortage with the Highest Frequency (Percent), 2012

List of Tables:

  • Table 8-1: United States-Anesthesia Market Merger & Acquisitions (M&A), Jan 2016-March 2017
  • Table 9-1: Coventry Health Care-Anesthesia Modifiers, 2016
  • Table 9-2: Blue Cross and Blue Shield of Texas-Physical Status Modifiers, 2017
  • Table 9-3: Blue Cross and Blue Shield of Texas-Qualifying Circumstances, 2017
  • Table 9-4: Blue Cross and Blue Shield of Texas-Modifier Information Billed by an Anesthesiologist, 2017
  • Table 9-5: Blue Cross and Blue Shield of Texas-Modifier Information Billed by a CRNA, 2017
  • Table 9-6: Blue Cross and Blue Shield of Texas-Anesthesia Modifier Reimbursement
  • Table 9-7: UnitedHealthcare Community-Modifiers, 2017
  • Table 10-1: Medicare-Reimbursement Formulas
  • Table 10-2: Medicare-General and Monitored Anesthesia Care
  • Table 10-3: Medicare-Anesthesia Modifiers, 2017
  • Table 10-4: MDwise -Type of Service & PA Requirement
  • Table 10-5: MDwise-Anesthesia Time Table, 2017
  • Table 10-6: MDwise-Qualifying Circumstances, 2017
  • Table 10-7: MDwise-Status Modifiers, 2017
  • Table 11-1: United States-Cardiovascular Disease Prevalence (Percent), 2010,2015,2020,2025, 2030
Back to Top